Research suggests that copper peptide exhibits measurable neuroprotective effects in preclinical models by reducing inflammation, limiting cellular damage, and supporting neuronal survival. Findings come from models relating to ageing and cognitive decline, as well as studies into acute brain injury, indicating that copper peptide acts on key biological processes responsible for maintaining brain function.
In studies using models of aging mice, intranasal administration of a copper peptide at a dose of 15 mg/kg for two months led to improvements in memory and learning ability. The animals subjected to the therapy performed better in behavioural tests, such as the Y-maze and Box Maze, compared to control groups. At the tissue level, this improvement was associated with lower levels of neuroinflammation markers, including MCP-1, and a reduction in signs of axonal damage, such as decreased levels of neurofilament light chain. This suggests that copper peptide may support the maintenance of neuronal structure and function in aging-related conditions.
At a molecular level, its neuroprotective action appears to involve the regulation of inflammation and oxidative stress. The copper peptide has been shown to reduce reactive oxygen species levels and increase the activity of antioxidant enzymes such as superoxide dismutase. This helps to limit oxidative damage, which is one of the factors leading to neuronal degeneration. Additionally, the peptide affects signalling pathways such as PI3K/Akt, which play an important role in cell survival and stress response.
Further information comes from research on intracerebral haemorrhage models. In these models, the copper peptide improved the recovery of neurological functions, reduced brain swelling, and increased neuronal survival. These effects were associated with changes in gene regulation, including increased expression of microRNA-146a-3p and reduced levels of AQP4, a protein linked to fluid accumulation in the brain. This indicates that the copper peptide may influence key molecular regulators associated with inflammation and cellular stress at both the gene and microRNA levels.
Copper peptide also appears to interact with broader gene expression patterns. Gene profiling studies indicate that it may shift gene activity towards processes related to repair and inflammation reduction. This includes pathways relevant to neurodegenerative diseases, where chronic inflammation and oxidative stress contribute to disease progression.
It should be stressed that the results presented are based on laboratory and animal studies. The observed neuroprotective effects do not confirm clinical efficacy in humans and should be interpreted solely in the context of research.
What neuroprotective mechanisms have been proposed for copper peptide (GHK-Cu)?
Copper peptide is thought to support neuroprotection through several interconnected mechanisms. These mainly include reducing inflammation, limiting oxidative stress, and regulating the activity of genes associated with neuronal survival and function. Together, these processes help explain how the peptide may protect brain cells under stress.
One of the main mechanisms is its anti-inflammatory action. Copper peptide has been shown to lower levels of pro-inflammatory molecules, such as TNF-α and IL-1β, in models related to the nervous system. It also reduces the levels of MCP-1, a signalling molecule associated with neuroinflammation. By limiting these signals, it can reduce immune system activity, which over time can lead to neuronal damage. Additionally, the peptide affects microRNA pathways, particularly miR-146a-3p, which plays a role in regulating inflammatory processes.
Another important mechanism is the reduction of oxidative stress. Copper peptide helps to decrease levels of reactive oxygen species, which can damage brain cells. At the same time, it increases the activity of antioxidant systems, including enzymes such as superoxide dismutase. This dual action supports the protection of neurons from oxidative damage, which is often associated with ageing and neurodegenerative diseases. The peptide also binds metal ions, particularly copper, which can help to control oxidative reactions and limit cellular toxicity.
The third mechanism relates to cell survival signalling pathways. One of the key pathways is the PI3K/Akt pathway, which plays an important role in maintaining cell survival and protecting against stress. Activation of this pathway can reduce programmed cell death (apoptosis) and improve neurons' ability to cope with adverse conditions. This pathway is also linked to changes in microRNA activity, connecting signalling processes with gene regulation.
Copper peptides also affect fluid balance and protein regulation in brain tissue. They have been shown to lower levels of AQP4, a protein involved in water transport and the formation of brain oedema. By reducing AQP4 levels, they can limit oedema and secondary damage after brain injury. Concurrently, they interact with matrix metalloproteinases and their inhibitors, helping to maintain the stability of the cellular environment.
Ultimately, broader changes in gene expression are also significant. Copper peptide has been observed to affect genes related to repair processes, inflammation control, and antioxidant protection. These changes can shift cells towards a more protective and regenerative state, supporting overall brain resilience.
It should be emphasised that the described mechanisms are based on experimental and preclinical studies. They do not confirm therapeutic efficacy in humans and should be interpreted solely in the context of research.
Has copper peptide been studied in Alzheimer's disease models?
Yes, copper peptide has been studied in Alzheimer's disease models, where it has shown an effect on cognitive function, inflammation, and several biological features associated with neurodegeneration. In transgenic mouse models commonly used for studying Alzheimer's disease, the use of copper peptide has been linked to a delay in the deterioration of cognitive function and a reduction in markers associated with disease progression.
In a study, mice were administered copper peptide intranasally at a dose of 15 mg/kg several times a week for several months. Compared to untreated animals, the mice receiving the peptide showed improved performance in memory and learning tests. Researchers also observed a reduction in amyloid plaque formation, which is a hallmark of Alzheimer's disease pathology. Additionally, the peptide reduced inflammation in important brain areas such as the hippocampus, associated with memory, and the frontal cortex, which supports higher cognitive functions.
These results align with broader research indicating that copper peptide can influence the activity of genes associated with neurodegenerative diseases. Using gene-profiling tools, researchers demonstrated that GHK can shift or partially reverse gene expression patterns linked to neuronal damage and ageing. In simpler terms, this suggests its effects may extend beyond symptom-related changes to involve deeper molecular processes involved in cell protection and repair.
Copper peptide also demonstrated a protective effect against protein aggregation and metal-related toxicity. Protein aggregation means the abnormal clumping of proteins, a characteristic observed in many neurodegenerative disorders. In experimental models, copper peptide limited this aggregation under inflammatory stress conditions and helped protect cells from toxicity related to metal ions, such as copper and zinc, which, when dysregulated, are linked to neurodegenerative processes.
Further research has drawn attention to related mechanisms, including the reduction of oxidative stress, support for antioxidant systems, and the modulation of inflammatory signalling pathways, all of which are frequently analysed in Alzheimer's disease research. These overlapping mechanisms are one reason why copper peptides have generated interest in neuroprotective models.
Copper peptide used in research is available from suppliers such as SemaxPolska. It is worth highlighting that these results come from laboratory and animal studies and do not confirm its efficacy in treating Alzheimer's disease in humans.
What results were obtained for copper peptide (GHK-Cu) in animal studies concerning cognitive impairment?
In animal studies, copper peptide has repeatedly been linked to improvements in cognitive function, particularly in ageing models. For example, in a study involving 20-month-old mice, daily intranasal administration of copper peptide for eight weeks led to a significant improvement in memory and learning abilities.
In the Y-maze test, mice given the copper peptide exhibited a higher level of spontaneous alternation, indicating improved working memory. In the Box Maze test, the same animals found the exit route more quickly and made fewer errors, suggesting enhancements in spatial learning and memory. Importantly, these changes were not solely behavioural but were associated with measurable biological alterations in brain tissue.
It has also been shown that the copper peptide lowers levels of neuroinflammation markers, such as MCP-1, and reduces measures of axonal damage, including light neurofilament chain. This suggests that the observed cognitive benefits were associated with a reduction in inflammation and protection of neuronal structure, rather than solely with behavioural changes.
Other studies have analysed the effects of copper peptide under stress conditions. In models where memory impairments were induced by factors such as sleep deprivation, animals treated with copper peptide retained their learning abilities. Lower levels of inflammation and oxidative stress markers were also reported in the hippocampus, which plays a key role in memory and learning processes.
Collectively, these findings suggest that copper peptide may enhance resistance to cognitive decline by simultaneously acting on several biological pathways. These include reducing inflammation, limiting oxidative stress, and supporting neuronal and brain tissue integrity. It should be noted that the cognitive improvements observed in animal studies may not directly translate to the same effects in humans.
How does copper peptide affect oxidative stress in brain tissue in research models?
Copper peptide demonstrates the ability to reduce oxidative stress in brain tissue by lowering reactive oxygen species levels and strengthening the body's antioxidant systems. These effects have been observed in both cell studies and in animal models related to brain injury and ageing processes.
In inflammatory models, copper peptide limited the production of reactive oxygen species induced by stimuli such as lipopolysaccharide. At the same time, it increased the activity of antioxidant enzymes, including superoxide dismutase, which neutralises harmful free radicals. This combined action helps protect key cellular components, such as proteins, lipids, and DNA, from oxidative damage.
The peptide also affects oxidative stress markers in living organisms. In models of cognitive impairment, its use led to a reduction in nitrotyrosine levels, an indicator of oxidative protein damage. This suggests that copper peptide not only limits the generation of oxidative stress but also reduces its impact on cell function.
Its ability to bind copper ions is also an important element. Free copper in the body can promote the formation of reactive oxygen species, but after binding to the copper peptide, its activity becomes more controlled, reducing the risk of oxidative damage. This helps to maintain the redox balance in brain tissue.
The antioxidant activity of copper peptide is closely linked to improved neuronal survival and function. By limiting oxidative stress, it supports the preservation of cell structure and processes related to memory and learning.
Copper peptide used in research conditions is available through suppliers such as SemaxPolska. It should be highlighted that the reduction in oxidative stress observed in experimental models does not constitute confirmation of therapeutic effects in humans.
References
- Rosenfeld, M., Nickel, K., & Ladiges, W. (2023). GHK peptide prevents sleep-deprived learning impairment in aging mice. Pathobiology and Therapeutics of Ageing, 5(1), 33–35. https://doi.org/10.31491/apt.2023.03.109 https://pmc.ncbi.nlm.nih.gov/articles/PMC10081520/
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2012). The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative medicine and cellular longevity, 2012, 324832. https://doi.org/10.1155/2012/324832 https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/
- Zhang, H., Wang, Y., & He, Z. (2018). Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Resulting from Intracerebral Haemorrhage Via the miR-339-5p/VEGFA Pathway. Frontiers in neuroscience, 12, 644. https://doi.org/10.3389/fnins.2018.00644 https://pmc.ncbi.nlm.nih.gov/articles/PMC6158323/
- Zhang, H., Wang, Y., & He, Z. (2018). Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Resulting from Intracerebral Haemorrhage Via the miR-339-5p/VEGFA Pathway. Frontiers in neuroscience, 12, 644. https://doi.org/10.3389/fnins.2018.00644 https://pmc.ncbi.nlm.nih.gov/articles/PMC6158323/
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2014). GHK and DNA: resetting the human genome to health. BioMed Research International, 2014, 151479. https://doi.org/10.1155/2014/151479 https://pmc.ncbi.nlm.nih.gov/articles/PMC4180391/
- Pickart, Loren, Jessica Michelle Vasquez-Soltero, and Anna Margolina. „The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline.” Neuroscience 7, no. 2 (2017): 20. https://www.mdpi.com/2076-3425/7/2/20
- He, Qianpei. „Exploring the Neuroprotective Effects of GHK-Cu in-vitro with astrocyte C8-S and in-vivo with 5XFAD transgenic mice.” Master’s thesis, University of Washington, 2025. https://www.proquest.com/openview/b4b5b68aa4e2669074ca3063b2071cd3/1?pq-origsite=gscholar&cbl=18750&diss=y
- Pickart, Loren, and Anna Margolina. „Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.” International journal of molecular sciences 19, no. 7 (2018): 1987. https://www.mdpi.com/1422-0067/19/7/1987
- Tucker, M., Liao, G. Y., Park, J. Y., Rosenfeld, M., Wezeman, J., Mangalindan, R., Ratner, D., Darvas, M., & Ladiges, W. (2023). Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. bioRxiv: the preprint server for biology, 2023.11.20.567908. https://doi.org/10.1101/2023.11.20.567908 https://pmc.ncbi.nlm.nih.gov/articles/PMC10690187/
- Tucker, M., Keely, A., Park, J. Y., Rosenfeld, M., Wezeman, J., Mangalindan, R., Ratner, D., & Ladiges, W. (2023). Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv: the preprint server for biology, 2023.11.16.567423. https://doi.org/10.1101/2023.11.16.567423 https://pmc.ncbi.nlm.nih.gov/articles/PMC10680828/
- Zhang, Heyu, Yanzhe Wang, Ling Lian, Cheng Zhang, and Zhiyi He. „Glycine-Histidine-Lysine (GHK) alleviates astrocyte injury from intracerebral haemorrhage via the Akt/miR-146a-3p/AQP4 pathway.” Frontiers in Neuroscience 14 (2020): 576389. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.576389/full
- López-Guerrero, V. E., Posadas, Y., Sánchez-López, C., Smart, A., Miranda, J., Singewald, K., Bandala, Y., Juaristi, E., Den Auwer, C., Perez-Cruz, C., González-Mariscal, L., Millhauser, G., Segovia, J., & Quintanar, L. (2025). A Copper-Binding Peptide with Therapeutic Potential against Alzheimer’s Disease: From the Blood-Brain Barrier to Metal Competition. ACS Chemical Neuroscience, 16(2), 241–261. https://doi.org/10.1021/acschemneuro.4c00796 https://pmc.ncbi.nlm.nih.gov/articles/PMC11741003/
- Caetano-Silva, M. E., Rund, L. A., Vailati-Riboni, M., Pacheco, M. T. B., & Johnson, R. W. (2021). Copper-Binding Peptides Attenuate Microglia Inflammation through Suppression of NF-kB Pathway. Molecular Nutrition & Food Research, 65(22), e2100153. https://doi.org/10.1002/mnfr.202100153 https://pmc.ncbi.nlm.nih.gov/articles/PMC8612997/